Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Taisho Pharmaceutical Holdings Co., Ltd.    4581   JP3442850008

TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.

(4581)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Tokyo Stock Exchange
01/18/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
7030 7050 7170 6810 6780 Last
65000 90300 84300 473000 335300 Volume
-0.14% +0.28% +1.70% -5.02% -0.44% Change
Financials
Sales 2021 294 B 2 830 M 2 830 M
Net income 2021 14 967 M 144 M 144 M
Net cash position 2021 249 B 2 398 M 2 398 M
P/E ratio 2021 36,3x
Yield 2021 1,52%
Sales 2022 290 B 2 797 M 2 797 M
Net income 2022 15 767 M 152 M 152 M
Net cash position 2022 272 B 2 625 M 2 625 M
P/E ratio 2022 34,6x
Yield 2022 1,52%
Capitalization 541 B 5 214 M 5 214 M
EV / Sales 2021 1,00x
EV / Sales 2022 0,93x
Nbr of Employees 9 354
Free-Float 51,2%
More Financials
Company
Taisho Pharmaceutical Holdings Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture and sale of over-the-counter drugs, quasi-drugs, foods, medical supplies, hygiene products, and ethical drugs. The Company operates in two business segments. The Self-Medication segment is engaged in the research, development, manufacture and sale of over-the-counter drugs, quasi-drugs, foods,... 
Sector
Pharmaceuticals
Calendar
02/04Earnings Release
More about the company
Notations Surperformance© of Taisho Pharmaceutical Holdings Co., Ltd.
Trading Rating : Investor Rating :
More Ratings
All news about TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.
2020TAISHO PHARMACEUTICAL HOLDINGS CO., : Ex-dividend day for interim dividend
FA
2020Takeda to sell Japan consumer health unit valued at $2.3 billion to Blackston..
RE
2020Takeda to sell Japan consumer health unit valued at $2.3 bln to Blackstone
RE
2020Takeda preparing to sell Japan consumer health unit to Blackstone - Kyodo
RE
2020Takeda preparing to sell Japan consumer health unit to Blackstone -Kyodo
RE
2020GLOBAL MARKETS LIVE: A flurry of earnings reports, day 3
2020EXCLUSIVE : Blackstone, Taisho Pharma among final bidders for Takeda's Japan OTC..
RE
2020Japan's Takeda sells $670 million of Europe OTC assets to pare debt
RE
2020TAISHO PHARMACEUTICAL HOLDINGS CO., : Ex-dividend day for final dividend
FA
2019TAISHO PHARMACEUTICAL HOLDINGS CO LT : Ex-dividend day for interim dividend
FA
2019TAISHO PHARMACEUTICAL HOLDINGS CO LT : Ex-dividend day for final dividend
FA
2018Bristol-Myers gets $1.6 billion offer for French consumer health unit
RE
2018Taisho said to near $1.6 billion deal for Bristol-Myers's UPSA- Bloomberg
RE
2018TAISHO SAID TO NEAR $1.6 BILLION DEA : Bloomberg
RE
2018TAISHO PHARMACEUTICAL HOLDINGS CO LT : Ex-dividend day for interim dividend
FA
More news
News in other languages on TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.
2020TAKEDA PHARMACEUTICAL : vende controllata giapponese farmaci da banco a Blacksto..
2020TAKEDA PHARMACEUTICAL : venderá a Blackstone su unidad de salud, valorada en 2.2..
2020Les GAFA, c'est plus fort que toi
2020EN DIRECT DES MARCHES : BNP Paribas, Air France-KLM, L'Oréal, Legrand, Vivend..
2019Le japonais Taisho finalise le rachat d'Upsa à Bristol-Myers
More news
Chart TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.
Duration : Period :
Taisho Pharmaceutical Holdings Co., Ltd. Technical Analysis Chart | 4581 | JP3442850008 | MarketScreener
Technical analysis trends TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 7
Average target price 6 507,14 JPY
Last Close Price 6 780,00 JPY
Spread / Highest target 10,6%
Spread / Average Target -4,02%
Spread / Lowest Target -14,5%
EPS Revisions
Managers and Directors
NameTitle
Akira Uehara President & Representative Director
Ken Uehara Director, Head-Audit, Finance & Legal Affairs
Masahiro Mino Finance Manager
Osamu Kitatani Head-Information Technology Planning
Akira Ohira Director